SAN FRANCISCO/SOUTH SAINT PAUL, Minn., June 25, 2019 – Veterinary Hospitals Association (VHA), a leading association for veterinary practices, announces its partnership with Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets. The alliance brings current — and future — products from KindredBio to more than 420 veterinary clinics.
“Partnering with an innovative pioneer in animal medicine like KindredBio is a massive benefit for our members and the veterinary industry,” says Jeff Benson, executive director of VHA. “It’s a very exciting opportunity for our veterinary members, and we look forward to a long-lasting relationship with KindredBio.”
VHA is a member-driven association representing the interests of members and the veterinary community. It serves over 420 veterinary practices, providing group purchasing, reliable cremation, business solutions, and continuing education opportunities.
KindredBio is one of the only veterinary biopharmaceutical companies in the world and is focused on bringing validated human molecules and innovative new technologies to veterinary medicine. In 2018, KindredBio launched Mirataz® (mirtazapine transdermal ointment), which is the first and only FDA-approved transdermal medication for the management of weight loss in cats. In addition, the company has an exciting pipeline of products for cats, dogs, and horses in development.
As part of the partnership agreement, VHA members will now have access to Mirataz — and future KindredBio products as they are available.
“We are excited to bring Mirataz to VHA member veterinarians,” says Denise Bevers, president and chief operating officer of KindredBio. “Unintended weight loss is a significant health concern affecting millions of cats. With Mirataz, veterinarians now have a tool to address weight loss quickly and early. Mirataz provides consistent drug delivery, proven safety and efficacy, and convenient application. The product can help manage unintended weight loss resulting from many diseases and stressors cats face — without needing to pill or hide medication in the food of a cat that might already be nauseated or vomiting. Mirataz can be an integral part of the therapeutic plan for any cat experiencing unintended weight loss, and we look forward to working with VHA.”1,2,3
Important Safety Information
Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients. Do not use in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves when handling/applying, wash hands after, and avoid contact between the treated cat and people or other animals for 2 hours following application. Use with caution in cats with hepatic and kidney disease. Cat’s food intake should be monitored upon discontinuation. Safety has not been evaluated in cats less than 2 kg, less than six months of age, or in breeding, pregnant, or lactating cats. The most common adverse reactions observed during clinical trials were application site reactions, behavioral abnormalities (vocalization and hyperactivity), and vomiting. For product label, including complete safety information, visit https://kindredbio.com/mirataz-pi.
About Kindred Biosciences
Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for cats, dogs, and horses. The company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.
Visit http://kindredbio.com for more information.
About Veterinary Hospitals Association
Established in 1984, Veterinary Hospitals Association (VHA) is a member-driven association organized to represent the interests of members and the veterinary community. VHA currently serves over 420 member veterinary practices. The goal of VHA is to enhance the profitability of each member practice by positively impacting its bottom line. With member involvement, VHA will continue to offer services that either save money or make money for all members. Follow VHA on Twitter, Facebook, and LinkedIn.
1 Data on file. Kindred Biosciences. American Pet Products Association (APPA), 2017-2018 National Pet Owners Survey (n=22,202 respondents). 2017 Mirataz Pricing Research, Kynetec, September 2017 (n=204 U.S. small animal veterinarians).
2 Buhles W, et al. Single and multiple dose pharmacokinetics of a novel transdermal ointment in cats. J Vet Pharmacol Ther. 2018;41(5):644-651.
3 Mirataz® (mirtazapine transdermal ointment) [package insert], Kindred Biosciences, Inc. (Burlingame, CA). Rev. 5/2018.
Mirataz® is a registered trademark of Kindred Biosciences, Inc. in the United States and/or other countries.
© 2019 Kindred Biosciences, Inc., Burlingame, CA 94010. All rights reserved.